Trilipix

Trilipix is a brand name of fenofibric acid, approved by the FDA in the following formulation(s):

TRILIPIX (choline fenofibrate - capsule, delayed release; oral)

• 
  Manufacturer: ABBOTT LABS
  
  Approval date: December 15, 2008
  
  Strength(s): EQ 135MG FENOFIBRIC ACID ^[RLD], EQ 45MG FENOFIBRIC ACID
  

Has a generic version of Trilipix been approved?

No. There is currently no therapeutically equivalent version of Trilipix available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trilipix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Salts of fenofibric acid and pharmaceutical formulations thereof
  Patent 7,259,186
  Issued: August 21, 2007
  Inventor(s): Cink; Russell Drew & Paterson, Jr.; Joseph B. & Gao; Yi & Zhang; Geoff G. Z. & Long; Michelle A. & Morris; John B. & Rosenberg; Joerg
  Assignee(s): Abbott Laboratories
  In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
  
  Patent expiration dates:
  
  
  • January 7, 2025
    
    ✓ 
    Drug substance
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 15, 2011 - NEW PRODUCT
  
  

See also...

• Trilipix Consumer Information (Drugs.com)
• Trilipix Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Trilipix Consumer Information (Cerner Multum)
• Trilipix Advanced Consumer Information (Micromedex)
• Fenofibric Acid Consumer Information (Wolters Kluwer)
• Fenofibric Acid Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Fenofibric acid Consumer Information (Cerner Multum)
• Fenofibric acid Advanced Consumer Information (Micromedex)